PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$24.69
+0.86%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.76
- Revenue estimate
- $182.2M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $0.73
- EPS estimate
- $0.65
- Revenue actual
- $192.4M
- Revenue estimate
- $191.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +7.0%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $31
- PT range
- $25 – $38
- Analysts
- 4
2 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $0.65 | $0.73 | Beat 13.00% | $192.4M |
| Apr 30, 2026 | $0.61 | $0.60 | Miss -1.64% | $177.4M |
| Nov 6, 2025 | $0.65 | $0.70 | Beat 7.69% | $179.5M |
| May 8, 2025 | $0.57 | $0.62 | Beat 8.77% | $168.9M |
| Feb 27, 2025 | $0.78 | $0.91 | Beat 16.67% | $187.3M |
| Jul 30, 2024 | $0.73 | $0.89 | Beat 21.92% | $178.0M |
| Feb 29, 2024 | $0.89 | $0.89 | Beat 0.11% | $181.2M |
| Nov 2, 2023 | $0.84 | $0.72 | Miss -13.88% | $163.9M |
| Aug 2, 2023 | $0.80 | $0.78 | Miss -2.74% | $169.5M |
| May 3, 2023 | $0.60 | $0.53 | Miss -11.52% | $160.3M |
| Feb 28, 2023 | $0.80 | $0.80 | Miss -0.37% | $172.0M |
| Nov 3, 2022 | $0.73 | $0.64 | Miss -12.33% | $167.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026